IPO Valuation Methods: A 2026 Practitioner Walkthrough

If you are preparing a company for a US listing, advising an issuer, or stress-testing an underwriter's price range, you need more than a list of methods. You need to know which method anchors the analysis for your sector, how the book-building process converts model outputs into an actual offer price, and what the SEC requires you to disclose about all of it in the S-1.

This walkthrough covers exactly that, with 2026 market context that the academic papers and generic trade-press articles ranking on this topic simply do not have.

Key takeaway: Investment banks never rely on a single valuation method. They triangulate across comparable company analysis, precedent transactions, and DCF, then let the book-building process adjudicate between them. The model sets the range; investor demand sets the price.

What IPO Valuation Methods Do Investment Banks Actually Use?

The five principal methods documented in both academic literature and practitioner practice are: comparable company analysis (trading comps), precedent transaction analysis, discounted cash flow (DCF), dividend discount model (DDM), and Economic Value Added (EVA). In practice, comps anchor the analysis for most sectors, DCF serves as a cross-check, and DDM and EVA are reserved for specific issuer profiles.

As Ferraro et al. in the International Journal of Business and Management (2020) summarise: "Discounted Cash Flow, Market Multiples, Dividend Discount Model and, even if just to some degree, Economic Value Added are the most popular methodologies in the valuation practice."

The table below shows how each method maps to issuer type and sector.

PwC's IPO Guide notes that valuation is iterative: an initial internal valuation is prepared 12-18 months before listing, updated as the S-1 is drafted, and refined again during the roadshow based on investor feedback. The final price is set the night before trading begins.

How to Run Comparable Company Analysis for an IPO

Comparable company analysis (trading comps) is the anchor method for most IPOs. The process involves selecting a peer group of publicly traded companies, calculating their valuation multiples, and applying those multiples to the issuer's financials to derive an implied equity value.

Here is the step-by-step process:

1. Define the peer group. Select 8-15 publicly traded companies with similar business models, revenue scale, growth profiles, and end markets. The peer set will be scrutinised by institutional investors on the roadshow, so it must be defensible.
2. Choose the right multiples for your sector. This is where most generic guides fail. The multiple that matters varies significantly by industry:
   • SaaS and cloud software: EV/NTM Revenue is now the primary multiple, having largely replaced EV/LTM Revenue, per KPMG's IPO Insights. The Rule of 40 (revenue growth rate plus EBITDA margin of 40% or more) is a key quality filter. SaaS companies meeting the Rule of 40 threshold have historically commanded EV/Revenue multiples 2-3x higher than peers below it, per Bain's analysis.
   • Industrials and established tech: EV/EBITDA and P/E are the standard anchors.
   • REITs: Price/FFO (funds from operations) replaces P/E as the sector norm.
   • Pre-revenue biotech: rNPV replaces comps as the primary method (see below).
   • AI and machine learning companies in 2025-2026: Traditional multiples are being supplemented by non-financial KPIs including GPU compute capacity, inference cost per query, and enterprise contract ARR, per Bloomberg reporting. These metrics appear in S-1 business descriptions but are not yet standardised, creating comparability challenges.
3. Calculate LTM and NTM multiples. LTM (last twelve months) uses reported financials. NTM (next twelve months) uses management projections, which introduces judgment and triggers additional SEC disclosure scrutiny under the MD&A guidance.
4. Apply a discount or premium. The issuer's multiple relative to the peer median reflects its growth rate, margin profile, and market position. A company growing 60% annually in a peer group averaging 25% growth will price at a premium to the median multiple.
5. Derive the implied price range. Apply the selected multiple range to the issuer's metric (revenue, EBITDA, earnings) to get an implied enterprise value, subtract net debt, divide by diluted shares outstanding.

The NYU Stern study of 2005 US IPOs found that the Price/Earnings multiple and the EV/LTM Revenue multiple were the most accurate forecasters of post-listing stock price among the comparables tested. Averaging the best-performing multiple with DCF results reduced underpricing relative to what underwriters actually achieved.

How to Apply DCF to an IPO, Including Pre-Revenue Companies

DCF estimates intrinsic value by projecting free cash flows and discounting them at the weighted average cost of capital (WACC). For a mature, cash-generative issuer, this is straightforward. For a pre-revenue or high-growth company, it requires navigating several structural problems.

The WACC problem. Pre-IPO companies have no observable market beta. Practitioners use the unlevered beta of comparable public companies, then re-lever for the target's capital structure, per Damodaran's valuation datasets at NYU Stern. His January 2026 dataset provides sector-specific WACC, EV/EBITDA, EV/Revenue, and P/E multiples and is the standard reference for practitioners building these analyses.

The terminal value problem. Terminal value typically accounts for 60-80% of total enterprise value in a DCF for a high-growth company, making the terminal growth rate assumption the single most sensitive variable in the model. This is where the "hockey stick" problem lives: investment banks and issuers routinely project aggressive revenue growth in years 3-5, which inflates terminal value. The SEC's MD&A interpretive release (Release No. 33-8350) requires that forward-looking statements in the S-1 have a reasonable basis, and SEC staff will push back on projections that appear unsupported.

For pre-revenue companies, the DCF output is almost entirely a function of terminal value assumptions, which makes it a weak standalone method. The honest approach is to use DCF as a sensitivity framework, showing how value changes across a range of growth and margin scenarios, rather than as a point estimate.

For biotech and pharma IPOs, the standard is risk-adjusted net present value (rNPV): each pipeline asset's cash flows are probability-weighted by clinical trial success rates at each phase, then discounted. Pipeline stage, indication, and competitive landscape drive valuation more than any financial history, per EY Life Sciences guidance.

Practitioner note: FASB ASC 820 governs fair value measurement in financial statements. Pre-IPO, companies must use Level 3 inputs (unobservable) for equity valuations, which is where DCF and option-pricing models are most relevant for stock-based compensation and financial instrument valuation. Post-IPO, the market price becomes the Level 1 input. Foreign private issuers using IFRS face the parallel framework under IFRS 13.

Precedent Transactions: The Ceiling, Not the Floor

Precedent transaction analysis benchmarks the issuer against M&A deal multiples from comparable companies. Because M&A transactions include a control premium, these multiples are structurally higher than trading comps, typically by 20-30% above the pre-announcement trading price of the target, per Corporate Finance Institute.

For IPO purposes, precedent transactions set an upper bound for valuation. An issuer cannot price above the control premium implied by comparable acquisitions without a compelling differentiation story, because institutional investors will immediately flag the comparison. Use precedent transactions to frame the ceiling of your valuation range, not the midpoint.

For the SPAC route specifically, the SEC's January 2024 final rules (Release No. 33-11265) now require that projections used in SPAC business combination disclosures meet a reasonable basis standard with enhanced disclosure of assumptions. This materially tightened the valuation discipline for de-SPAC transactions, where target companies had previously negotiated fixed enterprise values using aggressive forward revenue projections. See our SPAC vs IPO 2026 decision framework for the full comparison.

How Book-Building Converts Models into an Offer Price

The book-building process is the mechanism that connects valuation models to the actual offer price, and it is absent from almost every article on this topic.

Here is how it works in practice:

1. Preliminary range is set. Based on the comps and DCF analysis, the lead underwriter proposes a preliminary price range for the S-1 cover page. This range is typically 15-20% wide (e.g., $18-$21 per share).
2. Roadshow runs. Company management and underwriters present to institutional investors over 10-14 days. Investors submit non-binding indications of interest, specifying the number of shares they would buy at various price points.
3. The book is built. The underwriter aggregates demand across price levels. A book that is "covered" at the top of the range signals strong demand; a book that only covers at the midpoint signals the range needs to move down.
4. Final price is set. The night before trading begins, the underwriter and issuer agree on the final offer price, which may be within, above, or below the preliminary range depending on demand.
5. Greenshoe stabilisation. The underwriter holds an over-allotment option (the "greenshoe") typically sized at 15% of the offering, per SEC guidance. If the stock trades below the offer price post-listing, the underwriter buys shares in the open market to stabilise the price, effectively providing a floor.

For a detailed walkthrough of the pricing mechanics, see our IPO pricing process practitioner guide.

Direct listings work differently. When Spotify (2018), Palantir (2020), and Coinbase (2021) chose direct listings, there was no book-building and no underwriter-led price discovery. The opening price was set by the NYSE designated market maker (DMM) based on actual buy and sell orders on the first day of trading, per the SEC's final rule on direct listings (Release No. 34-89684). This eliminates the traditional underpricing mechanism but also removes the price support function of underwriters. See our direct listing vs IPO decision framework for the full comparison.

What the SEC Requires You to Disclose About Your Valuation

This is the gap that every ranking article on this topic leaves open, and it is the most important section for a finance professional preparing an S-1.

The SEC Form S-1 requires a section titled "Determination of Offering Price" (or equivalent) that explains the factors considered in setting the price range, including the company's financial condition, prospects, management, market conditions, and comparable companies. This is a regulatory disclosure obligation, not a best practice.

Beyond the offering price section, two additional disclosure issues require attention:

The 409A gap. For venture-backed technology companies, the common stock valuation used for stock option grants (the 409A valuation) is often a fraction of the expected IPO price. The SEC, through Staff Accounting Bulletin guidance, requires that companies disclose the basis for any significant difference between recent private valuations and the IPO price. If your 409A valuation was $8 per share six months ago and your IPO range is $18-$21, you need a credible narrative explaining the change, typically citing business milestones, market conditions, and the application of a marketability discount to the private valuation. Deloitte's IPO readiness framework identifies reconciling this gap as one of three critical valuation workstreams before listing.

NTM multiples and MD&A. If your comps analysis uses NTM (next twelve months) Revenue multiples rather than LTM, those forward projections must appear in the S-1 with a reasonable basis, per the SEC's MD&A interpretive release. SEC staff will scrutinise any hockey-stick revenue curve in years 3-5 of your DCF or NTM projections.

For the full S-1 disclosure framework, see our S-1 disclosure requirements guide.

Why IPOs Are Systematically Underpriced, and What That Means for Your Price Range

IPO underpricing is not an accident. It is a structural feature of the book-building process. Jay Ritter's long-running dataset at the University of Florida shows average first-day returns of approximately 16-18% for US IPOs over multi-decade periods. That gap between the offer price and the first-day closing price represents money left on the table by the issuer and transferred to institutional allocatees.

Underwriters underprice deliberately for several reasons: to reward institutional investors who provide honest demand signals during book-building, to ensure the IPO is fully subscribed, and to generate positive first-day momentum. From the issuer's perspective, underpricing is a cost, equivalent to selling shares below their clearing price.

The practical implication: if your comps analysis implies a midpoint value of $20 per share, expect the underwriter to propose a range of $16-$19. Negotiating the price range upward requires a heavily oversubscribed book. The NYU Stern study found that averaging the best-performing comparable multiple with DCF results reduced underpricing relative to what underwriters actually achieved in 2005, suggesting that a more rigorous triangulation of methods can support a higher offer price.

Also factor in the lock-up expiration. The standard 180-day lock-up period, per SEC guidance, constrains insider selling post-IPO. At expiration, significant selling pressure often occurs. Sophisticated investors price this dynamic into their assessment of IPO attractiveness. Our IPO lock-up agreement walkthrough covers the mechanics in detail.

The 2026 Market Context: What Has Changed

US IPO proceeds collapsed from approximately $155 billion in 2021 to approximately $22 billion in 2022, a decline of roughly 86%, per Ritter's dataset. The 2022-2023 drought reflected rising interest rates (which directly increase WACC and compress DCF values), multiple compression across growth equities, and the SPAC hangover after 613 SPAC IPOs in 2021 raised over $160 billion at peak-cycle valuations.

The recovery to approximately $35-40 billion in 2024 was partial but meaningful, led by AI infrastructure and healthcare listings. In 2025-2026, several high-profile AI and fintech IPOs have continued the recovery, with AI-sector companies commanding premium multiples supported by non-financial KPIs that are not yet standardised across S-1 filings.

Two structural shifts matter for practitioners building valuation models today:

• Interest rates and DCF. Higher-for-longer rates directly increase WACC, compressing the present value of terminal cash flows. A company that valued at 15x NTM Revenue in 2021 at a 7% WACC may only support 8-10x at a 10% WACC, all else equal. Damodaran's January 2026 sector WACC dataset is the current reference.
• NTM over LTM. For technology IPOs, EV/NTM Revenue has largely replaced EV/LTM Revenue as the primary multiple, per KPMG. This shift rewards growth trajectory over historical performance but adds a layer of projection risk and SEC disclosure scrutiny.

FAQ

What are the top 3 IPO valuation methods? In practice, the three methods that do the most work are comparable company analysis (trading comps), DCF, and precedent transaction analysis. Comps anchor the range, DCF cross-checks intrinsic value, and precedent transactions set the ceiling. The relative weight of each shifts by sector and issuer stage.

How is the IPO offer price actually determined? The offer price is set the night before trading begins, based on the book-building process. Underwriters collect non-binding demand indications from institutional investors during the roadshow, then use that demand data to set the final price within, above, or below the preliminary range filed in the S-1. Models set the range; investor demand sets the price.

What multiples are used for SaaS IPOs in 2026? EV/NTM Revenue is the primary anchor for SaaS and cloud software IPOs, supplemented by the Rule of 40 as a quality filter. Companies with revenue growth plus EBITDA margin of 40% or more have historically commanded EV/Revenue multiples 2-3x higher than peers below the threshold.

How does DCF work for a pre-revenue company going public? For pre-revenue issuers, DCF is almost entirely a terminal value exercise, making it highly sensitive to growth and margin assumptions. Most practitioners use it as a scenario framework rather than a point estimate. For biotech, rNPV (probability-weighted DCF by clinical trial phase) is the standard alternative.

What does the SEC require about IPO valuation disclosure? The S-1 must include a "Determination of Offering Price" section explaining the factors behind the price range. For venture-backed companies, SEC staff also require disclosure of any material gap between recent 409A private valuations and the IPO price range, with a narrative explanation of what changed.

What is the difference between IPO price and opening price? The IPO offer price is set by the underwriter and issuer the night before trading. The opening price is the first trade price on the exchange, determined by supply and demand on day one. The gap between them is the first-day return, which has averaged 16-18% historically in the US, representing the systematic underpricing built into the book-building process.